menu
    • menu
    [{"orgOrder":0,"company":"AKAVA Therapeutics","sponsor":"National Institute on Aging","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Funding","leadProduct":"AKV9","moa":"Undisclosed","graph1":"Neurology","graph2":"IND Enabling","graph3":"AKAVA Therapeutics","amount2":0.01,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Neurology","amount2New":0.01,"dosageForm":"Undisclosed","sponsorNew":"AKAVA Therapeutics \/ National Institute on Aging","highestDevelopmentStatusID":"5","companyTruncated":"AKAVA Therapeutics \/ National Institute on Aging"},{"orgOrder":0,"company":"AKAVA Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"AKV9","moa":"Undisclosed","graph1":"Neurology","graph2":"IND Enabling","graph3":"AKAVA Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"AKAVA Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"AKAVA Therapeutics \/ Inapplicable"}]

    Find Clinical Drug Pipeline Developments & Deals by AKAVA Therapeutics

    Menu

    AKAVA Therapeutics

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            AKAVA Therapeutics

                            U.S.A arrow
                            Interphex
                            Not Confirmed

                            AKAVA Therapeutics

                            U.S.A arrow
                            Interphex
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : AKV9

                            Therapeutic Area : Neurology

                            Study Phase : IND Enabling

                            Sponsor : National Institute on Aging

                            Deal Size : $7.3 million

                            Deal Type : Funding

                            DEALS_DEV arrow-down

                            Akava Therapeutics Celebrates $7.3M Grant to Study AKV9 in Neurodegeneration

                            Details : The funding will support Akava’s lead compound, NU-9 (AKV9). It is being evaluated for the treatment of Alzheimer’s disease and frontotemporal dementia.

                            Product Name : NU-9

                            Product Type : Other Small Molecule

                            Upfront Cash : Undisclosed

                            December 17, 2024

                            Lead Product(s) : AKV9

                            Therapeutic Area : Neurology

                            Highest Development Status : IND Enabling

                            Sponsor : National Institute on Aging

                            Deal Size : $7.3 million

                            Deal Type : Funding

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            AKAVA Therapeutics

                            U.S.A arrow
                            Interphex
                            Not Confirmed

                            AKAVA Therapeutics

                            U.S.A arrow
                            Interphex
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : AKV9

                            Therapeutic Area : Neurology

                            Study Phase : IND Enabling

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Akava Therapeutics, Inc. Announces FDA Clearance of Investigational New Drug Application for the Treatment of ...

                            Details : AKV9 (formerly NU-9) is a Protein aggregation inhibitor, which is being investigated in amyotrophic lateral sclerosis and improve the health of diseased upper motor neurons.

                            Product Name : AKV9

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            August 22, 2023

                            Lead Product(s) : AKV9

                            Therapeutic Area : Neurology

                            Highest Development Status : IND Enabling

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth